Cases of severely exacerbated CNS inflammation have been described in patients with MS under treatment with alemtuzumab, a pan-lymphocyte– depleting anti-CD52 monoclonal antibody. On the basis of the peripheral lymphocyte subset network (higher B-cell and suppressed T-cell counts) and marked clinical improvement following plasmapheresis and rituximab treatment (anti-CD20 antibody), a B-cell–dri...

Destruction of tumor cells by tackling of tumor-specific surface or intracellular properties and thus sparing normal tissues remains the ultimate goal of tumor therapy. Although none of the therapies available today completely match these requirements a number of new treatment modalities are getting closer to achieving this goal. In lymphoma, monoclonal antibodies binding to antigens specific t...

One of the fundamental tools in radiation biology is a formalism describing time-dose relationships. For example, there is a need for reliable predictions of radiotherapeutic isoeffect doses when the temporal exposure pattern is changed. The most commonly used tool is now the linear-quadratic (LQ) formalism, which describes fractionation and dose-protraction effects through a particular functio...

Diffuse large B cell lymphomas (DLBCL) are a highly heterogeneous subtype of Non Hodgkin Lymphoma (NHL), accounting for about 25% NHL. Despite an increased progression-free survival upon therapy, 40–50% patients develop relapse/refractory disease, therefore there remains important medical need. T recruiting therapies, such as the CD20xCD3 bi-specific antibody CD20-TCB (RG6026 or glofitamab), re...

BACKGROUND Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoc...

The anti-CD20 antibody rituximab has substantially improved outcomes in patients with B-cell non-Hodgkin lymphomas. However, many patients are not cured by rituximab-based therapies, and overcoming de novo or acquired rituximab resistance remains an important challenge to successful treatment of B-cell malignancies. Interferon-alpha (IFNalpha) has potent immunostimulatory properties and antipro...